By Meredith Wadman

Next month, the Obama-era US Food and Drug Administration (FDA) will confront what is likely to be the most defining moment in its short history. In a public meeting scheduled for mid-July, a committee of external experts will advise agency leaders—who may or may not accept their advice—on whether to ban a controversial diabetes drug implicated in causing heart attacks, when an equally effective competitor is also on the market, minus the heart attack risks. (Click here to continue reading)

Image by melloveschallah via Flickr Creative Commons